Objective: This study determined the effect of pulmonary disease on outcomes after endovascular abdominal (EVAR) and endovascular thoracoabdominal aortic aneurysm (eTAAA) repair. Methods: A prospective study of high-risk patients undergoing EVAR and eTAAA repair between 1998 and 2009 was used to contrast clinical and endovascular outcomes between patients with (group 1) and without (group 2) chronic obstructive pulmonary disease (COPD). COPD patients were classified in accordance with the severity of their pulmonary disease using the Global Initiative for Chronic Obstructive Lung Disease criteria. Survival, morphologic changes, and complications were assessed using Cox models and life-table analyses. The cause and timing of deaths between the groups was compared. Results: Of 905 patients analyzed, 289 (32%) had COPD (group 1) and the remaining patients (group 2) did not have COPD. EVAR was performed in 334 patients (37%), and fenestrated or branched devices were used in the remaining 571 (63%). Group 1 patients were younger (73.5 ؎ 6.7 vs 75.6 ؎ 8.2 years), had a better glomerular filtration rate (67.8 ؎ 25.8 vs 61.0 ؎ 23.3 mL/min/1.73 m 2 ), had higher hematocrits (41.6 ؎ 5.0 vs 40.5 ؎ 4.6), and had more extensive aneurysms. Mean follow-up was 39.5 ؎ 30.9 months. Early (3% vs 3%) and late (2% vs 1%) aneurysm-related deaths were similar between the two groups. Survival in group 1 depended on the severity of disease. Survival in patients with Global Initiative for Chronic Obstructive Lung Disease classification I and II was similar to group 2. Those with classifications III and IV demonstrated lower survival rates. Relevant pulmonary function test variables included a lower forced expiratory volume in 1 second and forced expiratory flow in the middle 50%, which were associated with decreased survival. Surrogate endovascular outcome analyses demonstrated that group 1 patients had fewer endoleaks (20% vs 25%; P ‫؍‬ .05) and more rapid sac shrinkage rate (1.66 mm/y difference; P < .001).
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death among Americans. 1 Severe COPD and dependence on home oxygen are perceived as relative contraindications to major abdominal surgery, 2 particularly when conventional repair requires a thoracoab-dominal incision resulting in increased perioperative pulmonary risk. 3 However, patients with COPD have an increased prevalence of abdominal aortic aneurysms (AAA) [4] [5] [6] and have a greater risk of rupture, even in the setting of small aneurysms, 7 underscoring the need for treatment of this patient population.
The critical clinical decision in such patients is whether patients will die of complications from their lung disease or rupture of an untreated aneurysm. Thus, the expected risk of complications in COPD patients must be established, and the long-term outcome of such patients should be assessed in the context of factors measured during preoperative testing. The application of endovascular aneurysm repair (EVAR) to mitigate risks in such patients 8 has been previously described and makes logical sense given the lack of need for large incisions that may detrimentally affect pulmonary function, among other factors. But the ability to do such procedures with limited perioperative morbidity must be viewed in the context of the longer-term benefits for pulmonary patients. Furthermore, given the knowledge that the presence of COPD has the potential to alter the growth and rupture risk of untreated aneurysms, the effect of pulmonary disease on the behavior of the aortic sac after EVAR or endovascular thoracoabdominal aortic aneurysm (eTAAA) repair must be examined.
METHODS
A prospectively collected database was analyzed for patients who underwent EVAR for infrarenal, juxtarenal, and TAA during 11 years, from 1998 to 2009. Patients were enrolled into one of two physician-sponsored investigational device exemption trials, one for infrarenal aneurysms 8 and one for juxtarenal/TAAs. 9, 10 All patients were considered high risk for open surgical repair 10 
Definition and classification of COPD
When preoperative pulmonary function tests were available. Pulmonary function tests (PFTs) were evaluated, and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, defined by the World Health Organization, were used to define and classify patients with COPD 11 (Table I) :
• The American Thoracic Society acceptability and reproducibility standards for spirometry were applied to all patients, 12 • Postbronchodilator values were used for evaluation, and • COPD was confirmed when a patient with symptoms compatible with COPD, including chronic cough and shortness of breath, was found to have nonreversible airflow obstruction, defined as forced expiratory volume in 1 second (FEV 1 )/forced vital capacity (FVC) ratio Ͻ0.70, and there was no alternative explanation for the symptoms and airflow obstruction (such as bronchiectasis).
When preoperative PFTs were not available. The following criteria were used to identify patients with sufficient evidence to diagnose COPD:
• Patients on supplemental home oxygen with no other explanation (eg, heart failure, obstructive sleep apnea) and a physician diagnosis of COPD, • Patients taking one to three classes of bronchodilators or anti-inflammatory inhalers (anticholinergics, ␤agonists, and inhalational steroids), or both, with no other explanation (such as pulmonary fibrosis) and a physician diagnosis of COPD, and • Patients who were not taking any medications for COPD at the time of the procedure but had a note by a pulmonologist or primary care physician, or both, identifying that they had COPD that had been previously evaluated with PFTs.
All patients considered to have COPD were classified into four grades of severity using the GOLD treatment guidelines and criteria that have been detailed in Table I .
Variables studied
Patients were grouped by those with COPD (group 1) and those without COPD (group 2). Preoperative variables collected included demographics, cardiovascular risk factors, PFT results, medications, maximum aortic diameter, and extent of the required aortic repair. Patients were grouped by smoking status as previous smoker, current smoker, or never smoked.
Three-dimensional modalities used in computed tomography angiography, including multiplanar reconstructions and centerline of flow analyses, were used to measure the maximum diameter of the aneurysm sac and the presence of endoleaks at all intervals in accordance with the Society for Vascular Surgery (SVS) reporting standards. 13, 14 The extent of aortic repair was defined as infrarenal, juxtarenal, and thoracoabdominal. Thoracoabdominal repair was further stratified using the Crawford classification. 15 Preoperative arterial blood gas values were not analyzed because they were only available for a small number of patients. Also recorded was the method of anesthesia administration (general, epidural or monitored sedation) and all factors related to pulmonary function postoperatively (time to extubation, need for reintubation, or tracheostomy need). Overall length of stay and number of days in the intensive care unit were also assessed.
Outcomes
The primary outcome for this study was all-cause mortality. Deaths were classified in accordance with the SVS Respiratory failure: arterial partial pressure of oxygen Ͻ8.0 kPa (60 mm Hg) with or without arterial partial pressure of carbon dioxide Ͼ.6.7 kPa (50 mm Hg) while breathing air at sea level. reporting standards. 13, 14 In addition to the review of medical records and quarterly phone calls, an automated query of the United States Social Security Death Index, performed every 3 months, was used to supplement results. The cause of death was confirmed by a review of stateissued death certificates, hospital death summaries, autopsy results, and discussion with family members. Additional analyses included an assessment of pulmonary and nonpulmonary deaths between the two groups. Sac size change, endoleaks, and the need for secondary endovascular interventions directed at the aortic repair were also compared between the two groups.
Statistical analysis
All data were captured and stored in a database (Oracle Clinical 4.03, Redwood Shores, Calif). S-plus 7.0 software (Insightful, Wash) was used for all statistical analysis. Continuous variables were expressed as mean Ϯ SD and categoric variables as number (percentage). Differences of variables between the two groups were tested with the t-test for continuous variables and the 2 test for categoric variables. Kaplan-Meier curves were used to analyze differences between the two groups with respect to survival and freedom from secondary interventions.
The association between the presence of COPD or other preoperative variables (demographic and clinical) and overall mortality was evaluated using the Cox model. Multivariable analysis was done with those variables associated with death with a P Յ .2 in the univariable analysis. A variable with a P Ͻ .05 in the multivariable analysis was considered independently associated with death. A similar analysis was done to find factors associated with a high mortality within the COPD cohort. A propensity score analysis was done to eliminate any differences and the effect of any confounding variables (such as smoking). The linear mixed model was used to analyze differences in aortic diameters with time.
RESULTS

Demographics and preoperative characteristics
We identified 905 patients, 289 with COPD (group 1) and 616 without COPD (group 2). Of these, 334 (37%) underwent infrarenal, 218 (24%) juxtarenal, and 353 (39%) TAA repair. The mean aneurysm diameter was similar between the two groups (6.5 Ϯ 1.3 vs 6.4 Ϯ 1.3 cm; P ϭ .4). Table II outlines the differences between the two groups. Most notably, patients in the COPD group were younger, had a higher glomerular filtration rate (GFR), had a higher hematocrit, and had more extensive aneurysms than non-COPD patients. Smoking, lung cancer, and the need for supplemental oxygen were more common in group 1, whereas hypertension and the use of ␤-blockers were less frequently noted. The distribution of severity of COPD among men and women within the COPD cohort was similar (P ϭ .9). 
Perioperative and postoperative features
The method of anesthesia used was similar across both groups, as was the need for reintubation and tracheostomy (Table III) . Group 1 had a longer duration of stay in the ICU (P ϭ .02) and a longer overall hospital length of stay (P ϭ .01). The time to extubation was also longer in the COPD group, although this was not statistically significant (P ϭ .07).
Survival analysis
The mean follow-up time was 39.5 Ϯ 30.9 months. There were no differences in the perioperative (30-day) survival (P ϭ .8; Table IV ). Estimated overall survival at 12, 36, and 60 months was, respectively, 82%, 60%, and 41% for group 1 and 89%, 74%, and 58% for group 2 (log-rank, P Ͻ .0001; Fig 1) .
During the follow-up period, 58 of 289 COPD patients (20%) and 46 of 616 of non-COPD patients (7%) died of pulmonary-specific causes (log-rank, P Ͻ .0001; Fig  2) . Nonpulmonary-related deaths were similar between the two groups (log-rank, P ϭ .47; Fig 3) . Of note, among the known causes of nonpulmonary-related deaths, half occurred as a result of cardiac issues in both groups: 31 of 62 (50%) in COPD patients vs 74 of 153 (48%) in non-COPD patients.
A decreasing survival trend (log-rank, P ϭ .08) was noted when survival was analyzed within the context of the severity grade for COPD patients (Fig 4, A) . However, combining patients with GOLD classifications III and IV resulted in a considerable survival disadvantage compared with patients with GOLD classifications I and II and patients who did not have COPD (group 2), with the inflection point of survival discrepancy occurring at 4.2 years (Fig 4, B) . The comparison of outcomes between groups 1 and 2 correlates well with our previously published scoring system intended to predict long-term survival in high-risk aneurysm patients. 16 In that scoring system, the presence of COPD accounted for 10% of the average score, and the need for supplemental home oxygen, 18% of the score. The combined hazard ratio for COPD and the use of home oxygen was 3.0 (95% confidence interval, 1.8-5.2). Percentages with reference to the total number of pulmonary specific deaths. 
Factors associated with a decreased patient survival
Overall population. On multivariate analysis, older patients, low GFR, low hematocrit, more extensive anatomic repairs, and larger baseline aortic diameters were all independently associated with decreased survival, with the presence of COPD showing a trend toward decreased survival (P ϭ .07). On univariate analysis, two specific PFT variables were noted to detrimentally affect survival: a low FEV 1 and a low forced expiratory flow in the middle 50% (FEF 25%-75% ; 
Secondary interventions
There were no differences in the requirement for secondary interventions between the two groups (log-rank, P ϭ .93; Fig 5) .
COPD, aneurysm sac behavior, and endoleak analysis
Despite a similar distribution of baseline aortic diameters, differences were noted with respect to morphologic changes after endovascular repair. The rate of sac shrinkage was significantly greater for group 1 patients (5.56 vs 3.90 mm/y; P Ͻ .001; Fig 6) . Of note, group 1 had a lower incidence of endoleaks (P ϭ .01), but the distribution of type of endoleaks was similar between the two groups (P ϭ .9).
The rate of sac shrinkage was 4.74 mm/y in the absence of endoleaks vs 3.10 mm/y with endoleak (P Ͻ .0001) for the population as a whole and 5.06 vs 3.50 mm/y (P ϭ .001) for COPD patients. However, a further analysis confirmed an independent association of COPD with beneficial sac behavior after adjusting for endoleaks, smoking history, and the use of aspirin (Table  VII) .
DISCUSSION
The ability to repair aneurysms with an endovascular approach has revolutionized patient management, with a primary benefit in decreasing pulmonary morbidity when compared with conventional procedures. Although EVAR was initially applied and advocated for patients considered to be high risk for an open surgical procedure, randomized trials found little short-term survival benefit in higher-risk patients compared with medical therapy. 17 Only recently have long-term data become available demonstrating a considerable mortality benefit for high-risk patients treated with EVAR in contrast to medical therapy. 18 Although these studies are of great interest to clinicians, the subjective manner in which patients were classified into surgically fit or unfit categories leaves clinicians with little guidance about optimal patient selection to achieve better perioperative and long-term results. Previous reports from our institution have focused on other risk factors and morbidities (cardiac, renal, or spinal cord ischemia). 9, [19] [20] [21] The intention of this report was to better define the perioperative risks and long-term benefits of EVAR in the pulmonary challenged patient. Poor pulmonary function is likely the most common risk factor deterring patients and clinicians from pursuing an open repair when a thoracotomy or thoracoabdominal incision is required. The absence of body cavity incisions likely will diminish the risk of any sort of pulmonary compromise, including long-term ventilator needs. In most series of open TAAA and descending thoracic aneurysm (DTA) repairs, the most common postoperative complications are respiratory. [22] [23] [24] Etz et al 25 reported an incidence of 27% who required ventilatory support Ͼ48 hours after open TAAA and DTA repairs, and 12% of these patients eventually died. Tracheostomy after TAAA and DTA repair occurs in 4% to 9% of patients, 26 most of whom suffer from baseline pulmonary dysfunction, and this complication has been reported to be associated with a high mortality rate. In a series of 1414 patients reported by Svensson 27 and Money, 28 112 (8%) had pulmonary complications requiring tracheostomy, and 45 (40%) died in the hospital.
It is obvious from these data that the detrimental impact of endovascular procedures on pulmonary function is considerably less than that of open surgery. There were no differences in short-term survival and only slightly longer intubation times and hospital stays in patients with severe lung disease, whereas the need for tracheostomy was exceedingly low and similar between groups 1 and 2 (3% each), with a subanalysis of EVAR patients only demonstrating an even lower tracheostomy rate of 1.4%. If the perioperative differences between COPD patients and non-COPD patients are neutralized, then the sole question that confronts clinicians caring for aneurysm patients will be whether there exists an overall survival benefit justifying aneurysm repair.
An overall assessment of the cause of death will provide some clues about how to optimally pick patients. It is not surprising that despite a slightly younger age and better renal function than non-COPD patients, the overall survival for patients in group 1 was lower than in group 2. The presence of a greater number of pulmonary deaths in group 1 of 20% compared with 7% in group 2 is intuitively obvious. Yet, when pulmonary deaths are eliminated from the survival analysis from both groups, the survival curves become nearly identical (Fig 3) . Cardiac deaths predominate the mortality statistics in both groups at a nearly equal level. Thus, any potential treatment directed at improving lung function in COPD patients should prolong life expectancy in this subgroup of EVAR patients, and attention must be focused in this direction. Of note, ␤-blockers are not used in patients with significant lung disease owing to their bronchoconstrictive effect. Thus, any survival benefit that may occur by ␤-blocker management will not be enjoyed by COPD patients, an effect that may further compound differences.
Survival differences must also be viewed in the context of aneurysm rupture risk. It has been well documented that COPD, along with aneurysm size, hypertension, and female sex, all increase the risk of rupture of a given aneurysm. 29 The etiology of this may relate to the link with smoking, which causes an activation of neutrophil-derived elastase (which is often elevated in COPD patients) that is present in both the lungs and aorta, resulting in degradation of elastin in both the aortic wall and lung. 30, 31 Others consider the relative alkaline state to be detrimental with respect to collagen degradation. The balance between an increased rupture risk and decreased long-term survival must be viewed in the context of an individual patient until we have more specific data about how to affect rupture risk in this population.
An increasing age, lower GFR, lower hematocrit, larger aortic aneurysm diameter and extent of aneurysm repair, along with COPD and some other factors, in various combinations, are associated with poor outcomes in patients undergoing EVAR. 16, 32 Anemia has been associated with increased mortality, 33, 34 an observation strengthened by our analysis, both overall and within COPD patients. However, anemia and decreasing renal function have multiple causes that were difficult to elucidate in this patient population.
PFT results can provide specific data on individual patients that can be related to outcomes in this series. [35] [36] [37] A low FEV 1 and FEF 25%-75% were univariably associated with increased death, both in the overall and COPD population. However, because PFT results were obtained only in patients with baseline pulmonary dysfunction, these parameters could not be used in the final multivariable analysis. Surprisingly, the need for supplemental home oxygen was not independently associated with early or late survival. This being said, patients with extremely poor pulmonary function were likely not even offered EVAR. Also, the hazard ratio in the total population for home oxygen use was 0.8, which is Ͻ1.0. This can be explained by the fact that this is a high-risk study population; thus, it is possible that the pulmonary disease qualifying the patient as high risk is less of a negative determinant on survival than other comorbidities such as severe cardiac or renal issues. These results indicate that EVAR/eTAAA can be performed in patients with severe COPD, even when supplemental home oxygen after pulmonary optimization is required.
Mortality risk is higher among patients who have moderate or severe COPD identified by baseline spirometry data. 38 As shown by the Kaplan-Meier analysis in our study, a decreasing survival trend, not meeting statistical significance, was noted over the course of patient follow-up within the COPD cohort with increasing severity of the disease. So, even though COPD itself does not affect survival in a strict statistical manner, the presence and the severity of COPD does have a negative effect on long-term survival, with survival discrepancy occurring at 4.2 years between the two groups.
It is very interesting that multiple studies have noted the favorable effect that COPD has on EVAR surrogate (radiographic) outcomes. 39 A lower endoleak rate and greater speed of sac shrinkage are both perceived as optimal situations. That is not to say that we should encourage our patients to smoke after EVAR, but there is clearly an effect of smoking on decreasing the risk for persistent sac flow 40 as well as on the speed of aneurysm resorption. Is this due to a higher incidence of peripheral vascular disease, perhaps resulting in smaller lumbar collaterals or an aortic wall that is partially ischemic? Are there specific effects of nicotine on the blood vessels resulting in constriction of perianeurysm small vessels leading to a higher rate of side-branch occlusion? It will be interesting to further evaluate the mechanisms; as such, discoveries may be applicable to non-COPD patients and provide them with improved morphologic results.
As with any nonrandomized trial, certain limitations exist in our study. The benefit of a prospective study is that there was attention to detail with respect to collection of preoperative data relating to pulmonary function and detailed collection of early and late adverse (pulmonary) events. The patient accountability in these studies is quite high (Ͼ80% at 2 years), yet often, despite questioning, patients with COPD may develop pulmonary complications that are expected in their minds, and thus we are not informed. Furthermore, patients with mild or no COPD rarely underwent PFT, which left us with incomplete pulmonary data for the entire patient cohort. Although many surgeons advocate routine PFTs before aneurysm repair (particularly TAA repair), we found this hard to justify in light of the relatively low risk of perioperative pulmonary issues. The absence of PFT studies in some COPD patients made it challenging to directly apply the GOLD criteria for severity stratification, which were modified slightly to account for such patients.
CONCLUSIONS
The effect of chronic, even severe, pulmonary disease in patients being treated with EVAR of AAA or TAA is minimal during the perioperative period. However, the life expectancy for an aneurysm patient with COPD is less than that of an aneurysm patient without COPD. The magnitude of the difference is partially quantified by an assessment of the FEV 1 and FEF 25%-75% . Clearly, patients with more severe COPD (GOLD classification III and IV) fare worse than those with less severe pulmonary disease, but the causes of death in both groups were similar. It is critical that attention be directed to optimizing the treatment of chronic lung disease after EVAR with the intent of optimizing results.
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